U.S. Machinery Stock News

NasdaqGS:METC
NasdaqGS:METCMetals and Mining

How A New Securities Class Action Against Ramaco Resources (METC) Has Changed Its Investment Story

Glancy Prongay Wolke & Rotter LLP previously filed a class action lawsuit in the U.S. District Court for the Southern District of New York against Ramaco Resources, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act for investors who bought securities between July 31, 2025 and October 23, 2025. This case, Henning v. Ramaco Resources, Inc., et al. (Case No. 1:26-cv-00846), introduces legal and disclosure questions that could influence how investors assess the...
NasdaqGS:MSTR
NasdaqGS:MSTRSoftware

US Stock Market Today: S&P 500 Futures Edge Higher On Surging Global Tech Demand

The Morning Bull - US Market Morning Update Monday, Feb, 9 2026 E mini S&P 500 futures are slightly higher this morning, with investors eyeing a powerful surge in global tech and chip demand. Taiwan’s exports rose 69.9% year on year in January to US$65.77b, led by electronics and information technology products. This signals strong appetite for the components that sit inside everything from smartphones to data centers. At the same time, China’s foreign exchange reserves stand at US$3.399t,...
NYSE:MANE
NYSE:MANEPharmaceuticals

Assessing Veradermics (MANE) Valuation After Recent 3.6% Share Price Move

Veradermics stock in focus after recent price move Veradermics (MANE) drew fresh attention after a single day gain of about 3.6%, putting the US$38.48 share price and the company’s dermatology focused pipeline on more investors’ radar. See our latest analysis for Veradermics. The 3.6% one day share price return comes after a relatively muted 1.9% year to date share price return, suggesting interest around Veradermics is picking up only gradually rather than in a sharp momentum shift. If this...
NasdaqCM:BLTE
NasdaqCM:BLTEPharmaceuticals

Belite Bio (BLTE) Valuation Check After Completing Enrollment In Pivotal DRAGON II Trial

Belite Bio (BLTE) completed enrollment of 60 adolescents in its global Phase 2/3 DRAGON II trial for tinlarebant in Stargardt disease type 1, marking a key clinical milestone that investors often watch closely. See our latest analysis for Belite Bio. The latest clinical milestone comes on top of a strong run in the shares, with Belite Bio’s 30 day share price return of 18.63% and 90 day share price return of 77.63%. Its 1 year total shareholder return of 249.18% and 3 year total shareholder...
NasdaqGS:ZS
NasdaqGS:ZSSoftware

Is It Time To Reassess Zscaler (ZS) After The Recent Share Price Slump

If you are wondering whether Zscaler is starting to look attractively priced or still expensive, this article will walk through what the current share price might be implying about its value. The stock last closed at US$167.33, with returns of 16.3% decline over 7 days, 22.8% decline over 30 days, 24.1% decline year to date and 18.6% decline over 1 year, set against a 25.0% gain over 3 years and 26.1% decline over 5 years. Recent news coverage has focused on Zscaler as a key name in cloud...
NasdaqGS:WSBC
NasdaqGS:WSBCBanks

WesBanco (WSBC) Is Up 5.2% After Strong Q4 EPS And New Preferred Dividend Plan – What's Changed

WesBanco, Inc. recently reported its fourth-quarter and full-year 2025 results, with quarterly net interest income rising to US$222.3 million and net income to US$91.11 million, and also announced that beginning in the first quarter of 2026, dividends on its Series B preferred stock will be US$4.24 million per quarter. An interesting angle for investors is that quarterly earnings per share improved year on year even as full-year earnings per share from continuing operations remained broadly...
NYSE:PBH
NYSE:PBHPharmaceuticals

How Mixed Q3 Results, Buybacks and Pillar5 Deal At Prestige (PBH) Have Changed Its Investment Story

In early February 2026, Prestige Consumer Healthcare reported third-quarter fiscal 2026 results showing lower sales and earnings, narrowed full-year revenue guidance to about US$1.10 billion, and detailed continued share repurchases and the recent Pillar5 acquisition amid supply constraints in its Clear Eyes brand. The company highlighted strong free cash flow, reduced leverage, and the flexibility to fund brand investment, selective M&A, and sizeable buybacks at the same time. With recent...
NasdaqCM:DNTH
NasdaqCM:DNTHBiotechs

How Investors Are Reacting To Dianthus Therapeutics (DNTH) US$600 Million Universal Shelf Registration

Dianthus Therapeutics, Inc. recently filed a universal shelf registration of up to US$600 million, covering common and preferred stock, debt securities, warrants and units, while also participating in the Guggenheim Emerging Outlook: Biotech Summit 2026 through a CEO fireside chat and investor meetings. This broad financing framework gives the clinical-stage biotech considerable flexibility in how and when it may access capital across different security types. Next, we will examine how the...